Statin therapy prior to ICU admission: Protection against infection or a severity marker?

Intensive Care Medicine

Volumn 32, Issue 1, 2006, Pages 160-164

  Fernandez, Rafael ^a   De Pedro, Victor Jose ^b   Artigas, Antonio ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b PARC TAULÍ HOSPITAL UNIVERSITARI   (Spain)

Author keywords

Hospital mortality; Immune therapy; Nosocomial infection; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HIGH RISK POPULATION; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; STATISTICAL ANALYSIS;

AGED; APACHE; COHORT STUDIES; CROSS INFECTION; FEMALE; HOSPITAL MORTALITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 29844438975     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-005-2743-9     Document Type: Article

References (16)

1. Walley T, Gallo PF, Schwabe U, Ganse on behalf of the EuroMedStat group (2004) Variations and increase in use of statins across Europe: data from administrative databases. BMJ 328:385-386
2. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, Rosa R, Hermanowski-Vosatka A, Wang PR, Zhang D, Peterson L, Detmers PA, Chao Y-S, Wright S (2001) Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 21:115-121
3. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakova O, Ford I, Capell HA, Sattar N (2004) Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomized placebo-controlled trial. Lancet 363:2015-2021
4. Real G, Jimenez-Baranda S, Mira E, Lacalle RA, Lucas P, Gomez-Mouton C, Alegret M, Peña JM, Rodriguez-Zapata M, Alvarez-Mon M, Martinez-A C, Mañes S (2004) Statins inhibit HIV-1 infection by down-regulating rho activity. J Exp Med 200:541-547
5. Marti-Fabregas J, Gomis M, Arboix A, Aleu A, Pagonabarraga J, Belvis R, Cocho D, Roquer J, Rodriguez A, Garcia MD, Molina-Porcel L, Diaz-Manera J, Marti-Vilalta JL (2004) Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 35:1117-1123
6. Lindenauer PK, Pekow P, Wang K, Gutierrez B, Benjamin EM (2004) Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA 291:2092-2099
7. Almog Y (2003) Statins, inflammation, and sepsis. Chest 124:740-743
8. Inoue K, Takano H, Yanagisawa R, Sakurai M, Yoshikawa T (2004) Statin, inflammation, and sepsis. Chest 125:2365
9. Munford RS (2001) Statins and the acute-phase response. N Engl J Med 344:2016-2018
10. Dechend R, Gieffers J, Dietz R, Joerres A, Rupp J, Luft FC, Maass M (2003) Hydroxymethyl-glutaryl coenzyme A reductase inhibition reduces Chlamydia pneumoniae-induced cell interaction and activation. Circulation 108:261-265
11. Liappis AP, Kan VL, Rochester CG, Simon GL (2001) The effects of statins on mortality in patients with bacteremia. Clin Infect Diseases 33:1352-1357
12. Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, Friger M, Zeller L, Danon A (2004) Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 110:880-885
13. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM (1988) CDC definitions for nosocomial infection. Am J Infect Control 16:128-140
14. Uusaro A, Kari A, Ruokonen E (2003) The effects of ICU admission and discharge times on mortality in Finland. Intensive Care Med 29:2144-2148
15. Metnitz PG, Fieux F, Jordan B, Lang T, Moreno R, Le Gall JR (2003) Critically ill patients readmitted to intensive care units-lessons to learn? Intensive Care Med 29:241-248
16. Pappachan JV, Millar B, Bennett ED, Smith GB (1999) Comparison of outcome from intensive care admission after adjustment for case mix by the APACHE III prognostic system. Chest 115:802-810